Rate of functional decline in Huntington's disease

Neurology

Volumn 54, Issue 2, 2000, Pages 452-458

  Marder, Karen ^a,f   Zhao, H ^b   Myers, R H ^c   Cudkowicz, M ^d   Kayson, E ^b   Kieburtz, K ^b   Orme, C ^b   Paulsen, J ^e   Penney Jr , J B ^d   Siemers, E ^g   Shoulson, I ^b  

^a The New York Presbyterian Hospital   (United States)

^b UNIVERSITY OF ROCHESTER   (United States)

^c BOSTON UNIVERSITY   (United States)

^d HARVARD UNIVERSITY   (United States)

^e UNIVERSITY OF IOWA   (United States)

^f and Epidemiology   (United States)

^g NONE

Author keywords

Functional decline; Huntington's disease

Indexed keywords

ADULT; ARTICLE; CLINICAL FEATURE; COGNITION; CONTROLLED STUDY; DISEASE COURSE; FEMALE; HUMAN; HUNTINGTON CHOREA; LONGITUDINAL STUDY; MALE; PHYSICAL CAPACITY; PRIORITY JOURNAL; SCORING SYSTEM;

EID: 0034711708     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: 10.1212/wnl.54.2.452     Document Type: Article

References (15)

1. Huntington Study Group. Unified Huntington's Disease Rating Scale: reliability and consistency. Mov Disord 1996;11: 136-142.
2. Benton AL, Hamsher K DeS. Multilingual aphasia examination manual. Iowa City: University of Iowa, 1978.
3. Smith A. Symbol digit modalities test manual. Los Angeles: Western Psychological Services, 1973.
4. Stroop JR. Studies of interference in serial verbal reactions. J Exp Psychol 1935;18:643-662.
5. Myers R, Sax D, Koroshetz W, et al. Factors associated with slow progression in Huntington's disease. Arch Neurol 1991; 48:800-804.
6. Shoulson I, Kurlan, Rubin A, et al. Assessment of functional capacity in neurodegenerative disorders: Huntington's disease as a prototype. In: Munsat TL, ed. Quantification of neurologic deficit. Boston: Butterworth, 1989:285-309.
7. Shoulson I. Huntington's disease: functional capacities in patients treated with neuroleptic and antidepressant drugs. Neurology 1981;31:1333-1335.
8. Shoulson I. Huntington's disease: anti-neurotoxic therapeutic strategies. In: Fuxe K, Roberts P, Schwarcz R, eds. Excitotoxins. London: MacMillan, 1982:343-353.
9. Laird NM, Ware JH. Random effects models for longitudinal data. Biometrics 1982;38:963-974.
10. Shannon KM, Raman R, Leurgans S. Primary clinical components of Huntington's disease: factor structure of the motorsubscale of the Unified Huntington's Disease Rating Scale. Neurology 1999;52(suppl 2):A120.
11. Mayeux R, Stern Y, Herman A, Greenbaum L, Fahn S. Correlates of early disability in Huntington's disease. Ann Neurol 1986;20:727-731.
12. Feigin A, Kieburtz K, Bordwell K, et al. Functional decline in Huntington's disease. Mov Disord 1995; 10:211-214.
13. American Psychiatric Association. Diagnostic and statistical manual of mental disorders, 3rd ed., revised. Washington, DC: American Psychiatric Association, 1987;222.
14. Shoulson I, Odoroff C, Oakes D, et al. A controlled clinical trial of baclofen as protective therapy in early Huntington's disease. Ann Neurol 1989;25:252-259.
15. Penney JB, Young AB, Shoulson I, et al. Huntington's disease in Venezuela: 7 years of follow-up on symptomatic and asymptomatic individuals. Mov Disord 1990;4:93-99.